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LABORATORY INVESTIGATION
Insulin and angiotensin II are additive in stimulating TGF-131
and matrix mRNAs in mesangial cells
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Insulin and angiotensin II are additive in stimulating TGF-131 and
matrix mRNAs in mesangial cells. Angiotensin II (Ang II) and insulin are
implicated in the mesangial cell hypertrophy and excessive accumulation
of mesangial matrix seen in glomerulosclerosis. Therefore, the effects of
Ang II with and without insulin on mRNA levels of several important
extracellular matrix genes and transforming growth factor beta-i (TGF-
131) were examined. Ang II alone (1 .sM) added to quiescent, murine
mesangial cells in serum-free, insulin-free media slightly but not signifi-
cantly increased TGF-131, fibronectin, collagen I, collagen IV and laminin
message levels. The slight elevations in message expression were reversed
by losartan, suggesting that these modest effects are mediated by the AT-i
receptor. Ang II alone also had no significant effects on TGF-131 and
extracellular matrix message levels in quiescent rat mesangial cells. In
contrast, significant increases in mRNA for collagen 1(6-fold), collagen IV
(4-fold), fibronectin 1(4-fold) and TGF-f31 (2-fold) were seen with insulin
alone (106 M) in rat mesangial cells, and a dose-response effect could be
demonstrated for insulin (10 to 10—6 M). Ang II plus insulin further
significantly increased collagen 1(9-fold), collagen IV (9-fold), fibronectin
1 (5-fold) and TGF-f31 (3-fold) message expression. These effects were
partially reversed in the presence of losartan. The Northern analyses were
supported by measurements of active and total TGF-/31 activity (pg/mI!
5 x 106 cells): 1145 76 and 1960 199, serum free control; 1i21 92
and 1932 214, Ang 11(10—6 M); 4589 103 (P < 0.001 vs. control) and
11071 1952 (P < 0.01 vs. control), insulin (10—6 M); and 6881 183
(P < 0.001 vs. control) and 16626 1435 (P < 0.01 vs. control), insulin
plus Ang II. These results suggest that insulin, itself, significantly increases
TGF-f31 and extracellular matrix gene expression in rat mesangial cells.
Ang II alone has modest effects, while Ang II and insulin have additive
effects. To explain the mechanism of these additive effects, we investigated
the action of Ang II on insulin signaling and the effect of insulin on Ang
II AT1 receptor mRNA expression. Ang II did not enhance insulin-
induced insulin receptor substrate-i (IRS-i) phosporylation or phospha-
tidylinositol3 (P1-3) kinase activity, but did enhance insulin-induced mito-
gen activated protein (MAP) kinase activity. Insulin increased message
levels of AT1 receptor by twofold. These results suggest that enhancement
of MAP kinase activity and AT1 receptor regulation by insulin may
contribute to the additive effects of insulin and Ang II in mesangial cells.
Expansion of the mesangium due to mcsangial cell hypertrophy
and accumulation of mesangial matrix is the hallmark of glomer-
ulosclerosis [11. In vivo studies implicate angiotensin II (Ang II) in
the pathogenesis of this process, since treatment of animals and
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humans in early stages of glomeruloscierosis with angiotensin
converting enzyme inhibitors (ACEIs) slows the progression of
the disease [2, 3]. A direct role for Ang II in glomerulosclerosis
has been inferred from in vitro experiments which demonstrate
that Ang II promotes mesangial cell growth [4, 5] and increases
the production of transforming growth factor-Ill (TGF-/31) and
extracellular matrix proteins in both primary mesangial cells [6]
and a transformed mesangial cell line [7]. Furthermore, blockade
of TGF-131 with neutralizing antibody abrogates the increase in
collagen in response to Ang II [6]. Thus, it is hypothesized that
Ang II promotes the progression of glomerulosclerosis by increas-
ing TGF-131, which then increases mesangial matrix production.
However, the independent effects of Ang II have been difficult to
clarify because of the presence of insulin in the mesangial culture
system. For example, in the study cited above [6], mesangial cells
were stimulated with Ang II in serum-free media containing 1 jIM
insulin (personal communication, NA. Noble); to what degree
insulin contributed to the final effect on matrix gene expression
was not determined. Insulin may play a role in the glomeruloscle-
rotic process, since in vitro studies have demonstrated that insulin
is a growth factor for mesangial cells, probably through its
activation of the insulin-like growth factor-I (IGF-I) receptor [8].
Both IGF-I and growth hormone have been shown to be poten-
tially important factors in the development of glonierulosclerosis
[9, 10]. Therefore, the goal of the present study was to examine
the effect of Ang II, both alone and with insulin, on the expression
of genes which encode extracellular matrix proteins as well as the
expression of TGF-p1, which may mediate this response in early
passaged murine and rat mesangial cells.
Methods
Materials
DMEM media with D-valine, trypsin-EDTA, penicillin/strepto-
mycin, bovine serum albumin, and antibodies to vimentin, desmin
and a-smooth muscle actin were purchased from Sigma Chemical
Co. (St. Louis, MO, USA). Human procollagen IV (al), collagen
I (aI), laminin B2, fibronectin 1 cDNA were obtained from
American Type Culture Collection. Murine c-fos and c-myc were
the gift of Dr. Amy Lee, USC. Murine TGF-p1 eDNA was the
kind gift of Dr. Rik Derynck, Genentech. Fetal calf serum was
purchased from Gemini Bioproducts (Calabasas, CA, USA).
Fungizone was purchased from GIBCO (Grand Island, NY,
745
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USA). Recombinant human insulin was purchased from Novo
Nordisk (Princeton, NJ, USA). Angiotensin II was purchased
from Peninsula Laboratories (Belmont, CA, USA). Losartan was
kindly supplied by Dr. Ronald Smith of Dupont-Merck Pharma-
ceuticals (Wilmington, DE, USA). Cytokeratin antibody was
purchased from DAKO (Carpinteria, CA, USA). Pan-specific
TGF-f31 neutralizing antibody was purchased from R&D Systems
(Berkeley, CA, USA). 32P-CTP (sp. act. 3000) was purchased
from JCN (Irvine, CA, USA).
Mesangial cells
Murine and rat glomeruli were isolated from normal adult
Swiss Webster mice and Sprague-Dawley rats using a modification
of a previously published method [4]. Glomerular cores were
plated out in DMEM media containing D-valine, 20% fetal calf
serum, 1 x 10—6 M recombinant human insulin, 100 lU/mi
penicillin, 100 sg/ml streptomycin, and 2.5 sg/ml amphotericin B.
Cells were maintained in a humidified environment of 5% C02-
95% air at 37°C and were fed three times a week. Glomerular
cores were left undisturbed for approximately three weeks, or
until mesangial cells were confluent. Tiypsin-EDTA was used to
detach cells, which were then replated at a ratio of 1:3. Cells were
subcultured at weekly intervals when nearly confluent and used
between the fourth and sixth passages. Each preparation of
mesangial cells were characterized before use by immunostaining
as previously described [11]. Mesangial cells stained positively for
a-smooth muscle actin, vimentin and desmin and negatively for
cytokeratin (data not shown). Preparations in which less than 95%
of the cells stained positively with a-smooth muscle actin were not
used.
Angiotensin II stimulation of murine mesangial cells
Non-confluent (50 to 70%) murine mesangial cells were placed
in serum-free, insulin-free (SFIF) media for 48 hours, then
stimulated with: (1) SFIF media only (control), (2) SFIF media +
Ang II (106 M), (3) SFIF media + Ang 11(10—6 M) + losartan
(10—i M). Ang TI-containing media was completely changed every
12 hours to ensure that adequate Ang II was present throughout
the incubation period. Cells treated with Ang II for two hours
were simultaneously treated with cycloheximide (10 ftg/ml final
concentration). RNA was harvested at 2, 12 and 24 hours. Each
treatment was performed in triplicate on 3 to 7 different prepa-
rations of mesangial cells (2 kidneys per preparation) resulting in
9 to 21 densitometric readings per treatment.
Angiotensin II stimulation of rat mesangial cells
In a separate group of experiments, non-confluent rat mesan-
gial cells were placed in SFIF media for 48 hours, then stimulated
with: (I) SFIF media only (control), (2) SFIF media + Ang II
(10_6 M), (3) SFIF media + insulin (106 M), (4) SFIF media +
Ang II (10—6 M) + insulin (10—6 M), and (5) SFIF media + Ang
11 (10 M) + insulin (106 M) + losartan (iO M). Ang
Il-containing media was changed every 12 hours to ensure that
adequate Ang II was present throughout the incubation period.
RNA was harvested at 12 and 48 hours. Each treatment was
performed in triplicate on three to seven different preparations of
mesangial cells (2 kidneys per preparation), resulting in 9 to 21
densitometric readings per treatment.
Insulin effects on mesangial cells
Insulin (10—p to 106 M) was applied to non-confluent rat
mesangial cells that had been placed in SFIF media for 48 hours.
The insulin-containing media was changed at 24 hours. RNA was
harvested at 48 hours. This experiment was performed in triplicate
on two different preparations of mesangial cells, resulting in six
densitometric readings per treatment.
RNA harvest and Northern blot analysis
RNA was harvested using a guanidinium-sodium acetate-phe-
nol-chloroform method [12]. Total RNA (20 jsg) was electropho-
resed through 1% agarose gels containing formaldehyde, then
RNA was transferred to charged nylon membranes (MSI, West-
boro, MA, USA) and cross-linked in a Stratalinker (Stratagene,
La Jolla, CA, USA). eDNA probes (32P-labeled using a random
primer method) were: procollagen IV (al), collagen I (al),
TGF-/31, laminin B2, fibronectin 1, c-fos, and c-myc, Ang II AT1
receptor. The approximate sizes of the transcripts were estimated
from the position of 18S and 28S bands. Densitometric scanning
was performed (LKB Ultroscan XL, Bromma, Sweden) on all
autoradiographs. The intensity of CHO-B (a constitutively ex-
pressed gene) was used to correct for loading of RNA in lanes.
The density of the bands corresponding to the gene being
investigated, obtained from cells treated with SFIF media only,
was used as a control and assigned a value of "1" and all other
values were expressed as "-fold increase relative to control."
Assay of TGF-/3 in culture media
TGF-f3 activity was determined as a measure of proliferation
inhibition using the mink lung epithelial cell line ATCC CCL-64,
as previously described [13]. Briefly, CCL-64 cells were seeded in
96 well microtiter plates at a density of 2 X iO cells/well in
Dulbecco's modified Eagle's medium supplemented with 100
U/mi penicillin, 100 jsg/ml streptomycin, 1% non-essential amino
acids and 10% fetal bovine serum. Culture supernatants were
added in triplicate to the wells for 18 hours. During the last six
hours of incubation 1 jsCi/well of 3H-thymidine (ICN Biochemi-
cals, Irvine, CA, USA) was added. Cells were then harvested on
glass fiber filters (Whatman, Maidstone, UK) using an automated
cell harvester (Cambridge Technology, Cambridge, MA, USA)
and 3H-thymidine incorporation measured in a scintillation
counter. A standard curve (TGF-pl concentration vs. percent of
inhibition) for each assay using recombinant TGF-/31 and un-
known values were interpolated from the standard curve. The
sensitivity of the assay was 100 pg/mi. Latent TGF-pl was
converted to the active form by treating culture supernatants with
6 N HC1 (final p1-I 2) for 20 minutes at room temperature, followed
by neutralization with 6 N NaOH/1 1-1 HEPES (1:1). Six different
preparations of mesangiat cells were used for murine sample
studies comparing serum free control versus Ang II (10 6 M).
Twelve preparations were used for rat studies comparing serum
free, Ang 11(10 ' M), insulin (106 M) and Ang II plus insulin.
These preparations were used to determine the insulin dose
response. Each sample was measured in duplicate.
Assay of MAP kinase activity
MAP kinase activity was measured by the in gel kinase assay
[14, 15]. Quiescent cells (24 hr in serum-free, insulin-free media)
were treated with insulin (10-6 M), Ang II (106 M) or the
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Table 1. Effect of angiotensin II stimulation alone on TGF-131 c-lbs and matrix c-myc expression
Hours after
Ang H treatment
(+ losartan)
TGF-pl
(+ losartan) c-fos c-myc
2 hours 2.66 0.46
(0.81 0.11)
0.08 0.32 0.95 0.27
12 hours 1.13 0.07
(1.05 0.24)
Fibronectin 1
(+ losartan)
2.79 0.94
(1.48 0.55)
Collagen I
(+losartan)
1.27 0.04
(0.82 0.08)
Collagen IV
(+losartan)
1.14 0.4
(1.00 0.12)
Laminin B2
(+ losartan)
1.08 0.28
(0.85 0.16)
24 hours 1.12 0.30
(1.31 0.31)
0.80 0.03
(1.10 0.40)
1.44 0.18
(1.04 0.09)
0.90 0.15
(0.58 0.02)
0.69 0.32
(0.90 0.26)
combination for 10 minutes. Cells are lysed in a buffer containing
50 mM sodium pyrophosphate, 50 mM NaF, 50 mM NaC1, 5 mM
EDTA, 5 mM EGTA, 100 jiM Na3VO4, 10 m'vi HEPES, pH 7.4,
0.1% Triton X-100, 500 jiM PMSF, and 10 jig/mi leupeptin, then
flash frozen on a dry ice/ethanol bath. After allowing the cells to
thaw, they were scraped off the dish and centrifuged at 14,000 rpm
(4°C for 30 mm), and protein concentrations were determined
using the Bradford protein assay (BioRad, Richmond, CA, USA).
Equal amounts of proteins (5 to 10 jig) were separated by
SDS-polyacrylamide gel electrophoresis through a gel containing
0.4 mg/ml myelin basic protein (MBP). The gel was then incu-
bated twice in buffer A (50 mi HEPES, pH 7.4, and 5 mM
13-mercapotoethanol) containing 20% isopropyl alcohol for 30
minutes, once in buffer A for one hour, twice in buffer A
containing 6 M quanidine HCI for 30 minutes, twice in buffer A
conaining 0.04% Tween 20 at 4°C for 16 hours and 2 hours, once
in buffer A containing 100 jiM Na3VO4, 50 jiM ATP, and 50 jiCi
of [U32PJATP for one hour at 30°C. The reaction was terminated
by washing the gel five to eight times in fixative solution contain-
ing 10 m sodium pyrophosphate and 5% trichloracetic acid for
15 minutes. The gel was dried and subjected to autoradiography.
Phosphotidylinositol 3 kinase (P13 kinase)
Quiescent cells were treated with growth factors as described
above for MAP kinase for five minutes. Reactions were termi-
nated by washing cells in PBS containing 1 mM CaC12, 1 mM
MgC12, and 100 m sodium vanadate to inhibit phosphatase
activity. Cells were lysed with 1% NP-40 in the presence of
protease inhibitors and sodium vanadate. After centrifugation,
cell lysates were incubated with 5 jig of P1-3-K-antibody (UBI,
Upstate, NY, USA) overnight at 4°C and were immunoprecip-
tated by addition of protein G-sepharose 4F beads (Pharmacia,
Uppsala, Sweden). P1-3 kinase activity was measured by adding
[32P1 ATP to phosphorylate phosphoinositol to phosphoinositol
phosphate which was visualized by thin layer chromatography
followed by autoradiography.
IRS-i assay using immunoblotting was performed as previously
described 16]. Mesangial cells were grown and maintained in
RPMI-1640 medium supplemented with 20% FBS in 5% CO2 at
37°C. Media were changed every three days. When the cells were
approximately 80% confluent, they were washed once and placed
in serum-free medium for 24 hours before use. They were then
treated with I jiM Ang II, I jiM insulin or the combination for 10
minutes at 37°C. After treatment, the cells were lysed. The lysate
was incubated on ice for 10 minutes and then centrifuged 10
minutes. The supernatant was stored at 80°C. The protein con-
centrations of all samples were determined by the Lowry method.
Proteins were separated on a 7.5% SDS-PAGE mini-gel and
transferred to a Hybridization Transfer membrane (Micron Sep-
arations Inc.). The membrane was blocked overnight in TBS
0.05% Tween-20 with 5% non-fat dry milk at 4°C, incubated with
anti-IRS-i (UBI), 1 jig/ml in TBS 0.05% Tween-20 with 1%
nonfat dry milk for two hours at room temperature, and subse-
quently washed with TBS containing 0.05% Tween-20 and then
incubated with 1:5000 dilution of goat anti-rabbit 1 g HRPO
conjugated (BioRad) in TBS containing 0.05% Tween-20 with 1%
nonfat dry milk for one hour at room temperature. After 10
washes with TBS containing 0.05% Tween-20, the labeled pro-
teins were visualized by enhanced chemiluminescence method.
The molecular weight of the protein bands were determined by
reference to the position of prestained molecular weight stan-
dards (BioRad).
Statistics
Data are expressed as mean SEM. Differences between groups
were analyzed using analysis of variance (ANOVA) on the
CLINFO System. Statistical significance was defined as P < 0.05.
Results
Murine mesangial cells: Effects of angiotensin II alone
Protooncogenes. There were no significant increases at 30
minutes, one or two hours in protooncogene expression in re-
sponse to Ang II alone, despite the addition of cycloheximide
(CHX) to stabilize message. Maximal c-fos and c-myc expression
in response to Ang II were 0.80 0.42-fold and 0.95 0.67-fold
relative to control at two hours, respectively (Table i).
Transforming growth factor-beta. After two hours treatment with
Ang II in the presence of CHX, TGF-131 message was increased
2.66 0.46-fold relative to control. In contrast, serum + insulin
(S+l) treatment under the same conditions increased TGF-f31
message by 6.43-fold (Fig. 1). At 12 hours, TGF-/31 message
expression decreased (1.13 0.07-fold, S+J: 2.10-fold). The
co-administration of losartan abolished the modest increased
expression of TGF-i mRNA at two hours in response to Ang II
(Table 1). While Ang II consistently induced increases in TGF-1
message, which were blocked by losartan, none of the increases in
TGF-1 message expression were statistically significant. These
data were in agreement with the lack of a change in either active
or total TGF-f31 levels in the media before or after Ang II
treatment: active, 1250 53 versus 1338 150 pg/ml/5 >< i0
A1 2 3 1 2 3
B
1 2 3
S
2
a
3
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Fig. 1. A. Northern blot of total RNA from quiescent murine mesangial cells
in serum-free, insulin-free media treated for two hours (in the presence of 10
tiM cyclohexamide) and probed with TGF-pl cDNA probe: Lane 1-Serum-
free media only, Lane 2—20% fetal calf serum + 1 IM insulin or Lane
3-Angiotensin II (10 M). B. Same Northern blot as A, re-probed with
cDNA probe for CHO-B (a constitutively expressed gene).
cells, and total, 2564 846 versus 3231 1501 pgImlI5 X 10
cells. Ang II also did not significantly increase the media levels of
TGF-/3 when applied to the CCL64 cells used to conduct the mink
lung assay (data not shown).
Extracellular matrix proteins. Relative changes in message levels
of the extracellular matrix proteins are also given in Table 1. After
12 hours of Ang II treatment, fibronectin 1 message was modestly
increased (2.79 0.94-fold relative to control, S+I: 2.72-fold), but
by 24 hours, this value had fallen (0.80 0.03-fold). Co-admin-
istration of losartan abolished the 12 hours increase in fibronectin
I mRNA in response to Ang II (Table 1 and Fig. 2). At 12 and 24
hours, collagen I expression was slightly increased; co-administra-
tion of losartan abolished the increase in collagen I mRNA in
response to Ang II (Table 1). There was little change in procol-
lagen IV or laminin f2 mRNA. Although responses to Ang II
were consistent and reproducible, changes in TGF-131 or collagen
I changes were not statistically significant.
Rat mesangial cells: Effects of insulin and angiotensin II
Because of the lack of Ang II effects on TGF-/31 and matrix
protein message levels in murine cells and previous data demon-
Fig. 2. A. Northern blot of total RNA from quiescent murine mesangial cells
in serum-free, insulin-free media treated for 12 hours and probed with
fibronectin 1 cDNA probe. Lane 1, Serum-free media only; Lane 2,
angiotensin II (10 M) and Lane 3, angiotensin II (10 M) + losartan
(10-s M). B. Same Northern blot as A, re-probed with cDNA probe for
CHO-B (a constitutively expressed gene).
Treatment
Seum-free, insulin-free 1.00 0.13 1.00 0.13
(control)
Angiotensin 11(1 tiM) 1.36 0.04 1.36 0.06
Insulin (1 jiM) 2.34 0.05a 2.35 0.04
Angiotensin 11(1 jiM) + 3.05 0.30 3.05 0.l8'
insulin (1 jiM)
Angiotcnsin 11(1 jiM) + 2.39 0.19' 2.40 0.18'
insulin (1 jiM) +
losartan (100 jiM)
P < 0.05 compared to control (SFIF)
' P < 0.05 compared to insulin alone
strating Ang II effects in rat cells [6], we compared Ang II, insulin,
and their combined effects on rat mesangial cells.
TGF-1. Ang II alone caused a minimal elevation in message at
12 hours, hut to a lesser degree than that seen in murine
mesangial cells (Table 2 and Fig. 3). Insulin alone resulted in a
significant increase in TGF-p1 message at 12 hours (2.34
0.05-fold relative to control), which persisted at 48 hours (2.35
0.04-fold). The combination of Ang II and insulin resulted in a
further significant increase in TGF-131 message at 12 and 48 hours
(3.05 0.30 and 3.15 0.18-fold, respectively). These increases
2 3
1 2 3
Table 2. Rat mesangial cells probed with TGF-j31
12 Hours
(fold-increase
above baseline)
48 Hours
(fold-increase
above baseline)
flØSs
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Fig. 3. Northern blot of total RNA from
quiescent rat mesangial cells in serum-free,
insulin-free media treated for 12 hours with:
Lanes 1 to 4, insulin (1 M); Lanes 5 to 8,
angiotensin II (1 pM) + insulin (1 pM); Lanes 9
to 12, angiotensin II (1 pM) + insulin (1 LM) +
losartan (lOg M). The blot was then probed
with TGF-131, collagen I, collagen IV,
fibronectin 1.
Table 3. Effect of insulin on TGF-pl and matrix mRNA levels in
mesangial cells
TGF-131 Fibronectin Collagen I Pro-collagen IV
SF 1.11 0.28 1.01 0.03 1.01 0.01 1.00 0.06iO 1.18 0.26 1.12 0.06 1.00 0.1 1.15 0.05l0 2.29 0.41 1.26 0.07 1.47 0.15a 1.49 o.06l0- 3.46 0.68" 1.65 0.066 1.66 0.14" 1.63 0.05'
10—6 4.99 0.926 1.89 0.05' 2.64 O.l5 2.67 0.17"
ap < 0.05
h < 0.01
were reversed by co-incubation with losartan (Table 2 and Fig. 3).
When insulin was added alone, the effect was dose-dependent
from 10 to 10-6 M (Table 3 and Fig. 4).
Similar to the results seen in mouse mesangial cells, Ang Ii
(10 M) alone had no significant effect on active or total TGF-pl
levels in the media: active, 1121 91 versus 1146 76 pg/ml/5 X
106 cells serum free control, and total, 1932 214 versus 1960
199 pglml!5 x 10' cells. In contrast, both forms responded to
i0 i0 10-8
Insulin, M
10-s SF
TGF-3
Fibronectin
CHO-B
Fig. 4. Northern blot of total RNA from quiescent rat mesangial cells in
serum-free, insulin-free media treated Jbr 48 hours with vaiying doses of
insulin. From left to right: I.ane 1, 106 Lanes 2 and 3, iO M; Lanes
4 and 5, i0 Lanes 6 and 7, l0 Lane 8, serum-free (SF) control.
insulin (10—6 M) alone, 4589 103 (P < 0.001 vs. control) and
1107 1952 (P < 0.01 vs. control) and increased even further
with Ang II plus insulin, 6881 183 (P < 0.001 vs. control and
TGF-j31
a
1 2 3 4 5 6 7 8 9 10 11 12
Collagen I
1 2 3 4 5 6 7 8 9 10 11 12
Collagen IV
1 2345678910fl12
Fibronectin 1
-
CHQ-B
t- -ass'ln
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Table 4. Rat mesangial cells probed with collagen I
Treatment
12 Hours
(fold-increase
above baseline)
48 Hours
(fold-increase
above baseline)
Serum-free, insulin-free 1.00 0.03 1.00 0.12
(control)
Angiotensin 11(1 ILM) 1.30 0.28 1.58 0.11
Insulin (1 tIM) 6.43 1.60' 3.31 0.27k'
Angiotensin 11(1 !.LM) + 8.94 1.58 3.47 o.17a
insulin (1 tIM)
Angiotensin 11(1 JIM) + 6.40 1.12 3.28 0.i0'
insulin (1 JIM) +
losartan (100 jIM)
a P < 0.05 compared to control (SFIF)
Table 5. Rat mesangial cells probed with procollagen IV (al)
12 Hours
(fold-increase
Treatment above baseline)
48 Hours
(fold-increase
above baseline)
Serum-free, insulin-free 1.00 0.06 1.00 0.08
(control)
Angiotensin 11(1 JIM) 0.96 0.08 1.17 0.36
Insulin (1 JIM) 4.44 0.43'
Angiotensin 11(1 JIM) + 4.85 0.53a
3.89 0.3P'
9.22 0.87k
insulin (1 tIM)
Angiotensin 11(1 jIM) + 4.83 0.16a 2.82 1.34a
insulin (1 jiM) +
losartan (100 jiM)
a P < 0.05 compared to control (SFIF)
6P < 0.05 compared to insulin alone
P < 0.05 vs. insulin alone) and 16626 1435 (P < 0.001 vs.
control and P < 0.015 vs. insulin alone). The effect of insulin alone
was dose-dependent (10 to i0 M): active, 1160, 1140, 1520,
2000 pg/mI 5 x 106 cells, respectively, and total, 4200, 4800, 9000,
and 12000 pglml/5 X 106 cells, respectively.
Collagen I. Ang II alone did not significantly change collagen I
message. Insulin alone resulted in a significant increase in colla-
gen I message at 12 hours (6.43 1.60-fold relative to control),
which decreased, but was still significant at 48 hours (3.31
0.27-fold increase). The combination of Ang II and insulin
resulted in a further, but non-significant increase in collagen I
message, especially at 12 hours (8.94 1.58-fold increase). These
increases were reversed by co-incubation with losartan (Table 4
and Fig. 3). The effect of insulin alone was significant at i0 M
(Table 3).
Procollagen IV (al). Ang II alone did not significantly change
procollagen IV (al) message. Insulin alone resulted in significant
increases in collagen IV message at 12 hours (4.44 0.43-fold
relative to control), which persisted up to 48 hours (3.89
0.31-fold). In addition, the combination of Ang II and insulin
resulted in a further significant increase in collagen IV message at
48 hours (9.22 0.87-fold). These increases were reversed by
co-incubation with losartan (Table 5 and Fig. 3). The effect of
insulin alone was significant at 10 M (Table 3).
Fibronectin 1. Ang II alone did not significantly change fi-
bronectin 1 message. Insulin alone resulted in approximately a
3.65 0.44-fold increase in fibronectin 1 message at 12 hours,
which fell slightly by 48 hours to 2.82 0.46-fold above baseline
(Table 6 and Fig. 3). The combination of Ang II and insulin
Table 6. Rat mesangial cells probed with fibronectin 1
Treatment
12 Hours
(fold-increase
above baseline)
48 Hours
(fold-increase
above baseline)
Serum-free, insulin-free 1.00 0.11 1.00 0.03
(control)
Angiotensin II (1 JIM) 0.92 0.07 0.93 0.02
Insulin (1 jiM) 3.65 0.44' 2.82 0.46'
Angiotensin 11(1 jIM) + 497 0.27L 2.36 0.07a
insulin (1 jiM)
Angiotensin 11(1 jiM) + 5.08 0.03a 2.41 0.0T'
insulin (1 jiM) +
losartan (100 jiM)
a P < 0.05 compared to control (SFIF)
'P < 0.05 compared to insulin alone
IRS-i )
— 203
—.-1i8
— 86
— 51
Fig. 5. IRS-I phosphoiylation in rat mesangial cells in serum-free, insulin-
free media (left lane), Ang II (106 Al, middle left lane), insulin (106 M,
middle right lane), and Ang II plus insulin (right lane). See text for details.
Ang II did not enhance the insulin effect.
resulted in a further significant increase in message to 4.97
0.27-fold at 12 hours falling back to baseline at 48 hours (2.36
0.07-fold). The effect of insulin alone was significant at i0 M
(Table 3).
Cellular insulin and Ang II interactions. When Ang II (10 M)
was administered with insulin (10_6 M), there was no enhance-
ment of the increase in IRS-i phosphorylation (Fig. 5) or P1-3
kinase activity (data not shown) that was seen with insulin alone.
However, although Ang II alone had no significant effect to
increase MAP kinase, it enhanced the insulin-induced increase in
MAP kinase (Fig. 6 A, B). In addition, insulin administration
alone up-regulated Ang II AT1 receptor mRNA levels by approx-
imately twofold (N = 4; P < 0.05) at 24 hours (Fig. 7). Ang II itself
down regulated the AT1 receptor mRNA levels; insulin prevented
the Ang II down-regulation.
Discussion
The present studies demonstrate that Ang II alone only mod-
estly and non-significantly increases the expression of TGF-/31
and fibronectin 1 in both primary murine and rat mesangial cells
in culture. Although Ang II is a hypertrophic factor for these cells
when tested in serum-free, insulin-free media [4], this growth
effect is not accompanied by an induction of protooncogene
expression, a finding similar to that of other investigators [17].
There were also no significant changes in the amount or type of
TGF-/31 in the media in response to Ang II alone, suggesting that
the modest early increases in TGF-/31 mRNA do not lead 10
significant changes in secreted TGF-pi protein. In contrast,
insulin alone (10—6 M) induced a moderate (2.5-fold) increase in
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Fig. 6. A. MAP kinase activity in mesangial cell extracts measured by the in
gel kinase method of insulin along but not Ang II alone in increases MAP
kinase activity in quiescent, cultured mesangial cells. Ang II enhances the
insulin effect. B. Densitometric analysis of MAP kinase activity. The data
represent mean SEM of 4 assays as shown in A. Control is quiescent cells
in serum-free, insulin-free media.
TGF-f31 expression and activity, as well as a substantial (> 4-fold)
increase in matrix protein expression in rat mesangial cells. The
effect of insulin was dose-dependent. Since insulin is a common
additive in mesangial cell media and is often used in so-called
"serum-free" media preparations, the finding that it has signifi-
cant effects on mesangial matrix and TGF-j31 message expression
is of importance. Moreover, Ang II and insulin have additive
effects to further significantly increase mRNA levels for collagens
I and IV, fibronectin 1, TGF-1 and TGF-f31 activity.
These results lead us to speculate that investigators who
demonstrated significant Ang II effects in early passaged mesan-
gial cell cultures may he observing a combined effect of insulin
and Ang II, rather than the effect of Ang 11 alone. Previous studies
[6], performed with rat mesangial cells placed in serum-free
media, have demonstrated that Ang II increased TGF-/31 message
expression up to sixfold at eight hours, which persisted at 48
hours. There was a 10-fold increase in active TGF-1, a threefold
increase in latent TGF-131 and statistically significant increases in
fibronectin and collagen I message/protein in response to micro-
molar amounts of Ang II. However, the serum-free media con-
tained 1 /.LM insulin and the media was hyperglycemic (NA.
Noble, personal communication). The fact that the authors [61
obtained more striking elevations in matrix messages might also
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Fig. 7. Insulin (10-6 si) treatment of cultured rat mesangial cells for 24
hours increases AT1 receptor message levels. Ang II (10' M) suppresses
AT1 receptor message levels, but this suppression is prevented by the
addition of insulin.
be due to the hyperglycemic conditions under which their cells
were grown, since hyperglycemia has also been shown to increase
matrix synthesis in mesangial cells [18—20]. We investigated the
effect of Ang II with and without insulin in the media at the same
concentrations as [6], but under normoglycemic conditions (100
mg/dl glucose).
There are known associations between insulin and Ang II
actions in mesangial and vascular smooth muscle cells. We
demonstrated that the addition of I xM insulin enhanced Ang
Il-induced increases in protein synthesis in cultured murine
mesangial cells [4]. Insulin has been shown to be necessary for
Ang Il-induced contraction of mesangial cells [21], for Ang
lI-stimulation of voltage-dependent calcium channels [22], and as
shown in the present study, necessary for Ang II stimulation of
TGF-f31 and extracellular matrix protein gene expression. In
order to investigate the cellular mechanisms of this additive effect,
we evaluated the action of Ang II to enhance the activity of cell
signaling pathways stimulated by insulin. Ang II did not affect
insulin-induced IRS-I phosphorylation or P13 kinase activity
which is a pathway thought to be important in mediating insulin's
metabolic events [231. However, Ang II did enhance insulin-
induced MAP kinase activity, which is a signaling pathway that
appears to mediate insulin's growth (and possibly other) effects
[24]. One previous study suggested Ang II stimulated MAP kinase
activity in quiescent rat mesangial cells, but it was unclear whether
insulin was present in the media [251. In addition, insulin in-
creased AT1 receptor message levels by twofold which is consis-
tent with previous data demonstrating an 86% increase in Ang II
binding following four days of treatment of rat mesangial cells
with insulin [22]. Receptor message levels or the Ang II receptor
subtype mediating the Ang II effect was not reported in that study
[221. We also observed that Ang II down-regulated AT1 receptor
message expression in the messangial cells, similar to the changes
previously reported in mesangial cells [26] and that we have
reported in rat cardiac fibroblasts [27]. We found in the present
study that insulin prevented the Ang II induced down-regulation
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of the AT1 receptor. In cultured bovine adrenal fasciculata-
reticularis cells, insulin-like growth factor-i (IGF-1) has been
reported to increase Ang II AT-i receptor message levels and
binding, which resulted in enhanced Ang II effects on corticoste-
roid production [281. These results suggest that the mechanisms
contributing to the additive effects of Ang II and insulin on
TGF-pl and extracellular matrix proteins involve enhancement of
MAP kinase activity, possibly due to the increase in AT1 receptor
message levels or the prevention of Ang 11-induced down regula-
tion caused by insulin.
IGF-i, itself, has been demonstrated to enhance procollagen ni
(I) and csl (IV) production and to promote hyperplasia in
cultured rat mesangial cells [29]. This observation is in agreement
with the insulin effect on matrix mRNA levels that we observed,
although we previously reported that insulin alone had hypertro-
phic and not hyperplastic effects on cultured rodent mesangial
cells [4]. We added insulin in serum-free media [4], while these
investigators added insulin in the presence of 0.5% FCS [29].
Whether insulin effects are mediated by the insulin or IGF-1
receptor is unclear. Feld et al [29] suggested IGF-i may contrib-
ute to glomerulosclerosis, although there are in vivo data that do
not support a role for IGF-1. Neither mice transgenic for IGF-1
nor rats injected with recombinant IGF-i for up to 60 days
develop glomerulosclerosis [10, 30]. Feld et al [29] concluded that
other factors may be necessary for IGF-i to induce glomerulo-
sclerosis in in vivo models.
Our data suggest that Ang II may be a factor in some models.
Increased renal levels of Ang II have been reported in the diabetic
rat [31] and increased vascular sensitivity to Ang II has been
reported in humans with diabetes [32]. Indeed, in humans and
animals, administration of angiotensin converting enzyme inhibi-
tors (ACEI) significantly slowed the progression of diabetic
nephropathy [2, 31. Hyperglycemia may be another factor in
diabetes [18—20]; tight glycemic control (near normoglycemia)
slows the development and progression of diabetic nephropathy
[33]. Both tight glycemic control and ACEI are now recom-
mended for prevention and treatment of diabetic renal disease.
Hypertension and mechanical stretch of mesangial cells is likely
another factor [34]. The present data suggest that Ang II and
insulin have additive effects on matrix production, and taken
together with the reports of IGF-i effects, the potential impact of
hyperinsulinemia merits further investigation.
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